Literature DB >> 19490655

Respiratory and gastrointestinal symptoms in esophageal atresia.

Fernando Maria de Benedictis1, Ascanio Martino.   

Abstract

Entities:  

Year:  2008        PMID: 19490655      PMCID: PMC2687539          DOI: 10.1186/1824-7288-34-5

Source DB:  PubMed          Journal:  Ital J Pediatr        ISSN: 1720-8424            Impact factor:   2.638


× No keyword cloud information.
Sir, Mastroianni et al. [1] report high prevalence (100%) of respiratory symptoms in their cohort of 19 children who received surgery for esophageal atresia. In contrast with the results of other studies [2], they found gastro-esophageal reflux incidence was low (26,3%). They therefore emphasize anti-reflux therapy could not be effective for treatment of respiratory symptoms in this group of patients. We agree with the speculation of the authors, as this was also our experience. Indeed, children who received surgical intervention for esophageal atresia have high incidence of respiratory function abnormalities [3] and bronchial hyperreactivity [4]. These conditions may be multifactorial in origin and are related to recurrent inhalation, epithelial damage, bronchial obstruction and tracheomalacia. Treatment of underlying respiratory disease instead of anti-reflux therapy may be warranted in children with a history of surgical repair of esophageal atresia and tracheoesophageal fistula, especially when lung function studies confirm respiratory involvement.
  3 in total

1.  Respiratory function in childhood following repair of oesophageal atresia and tracheoesophageal fistula.

Authors:  L Agrawal; C S Beardsmore; U M MacFadyen
Journal:  Arch Dis Child       Date:  1999-11       Impact factor: 3.791

2.  Lung function in children following repair of tracheoesophageal fistula.

Authors:  D W Milligan; H Levison
Journal:  J Pediatr       Date:  1979-07       Impact factor: 4.406

Review 3.  Long-term complications of congenital esophageal atresia and/or tracheoesophageal fistula.

Authors:  Thomas Kovesi; Steven Rubin
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.